Assembly Biosciences Presents Final Results of Phase 1b Study of ABI-H0731 at 2018 AASLD
Assembly Biosciences, Inc. (ASMB)
Last assembly biosciences, inc. earnings: 3/4 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.assemblybio.com/investor-relations
Company Research
Source: GlobeNewswire
First Presentation of HBV RNA Reduction Data, a Distinguishing Feature of Core Inhibitors SAN FRANCISCO, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, presented final data from the Phase 1b study of ABI-H0731 in patients with chronic HBV at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting (The Liver Meeting®), in San Francisco. “We are excited about our progress with ABI-H0731 and our deep pipeline of core inhibitors,” said Uri Lopatin, MD, Chief Medical Officer of Assembly Biosciences. “The HBV RNA data shown in our presentation at AASLD serves as an important marker of the core inhibitor mechanism and distinguishes it from standard of care nucleos(t)ide or ‘nuc’ therapy. We are currently evaluating ABI-H0731 in two Phase 2a studies and we also recently announced the i
Show less
Read more
Impact Snapshot
Event Time:
ASMB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ASMB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ASMB alerts
High impacting Assembly Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
ASMB
News
- Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent HighlightsGlobeNewswire
- Assembly Biosciences, Inc. (NASDAQ: ASMB) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- Assembly Biosciences, Inc. (NASDAQ: ASMB) had its "neutral" rating re-affirmed by analysts at HC Wainwright.MarketBeat
- Assembly Biosciences, Inc. (NASDAQ: ASMB) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent HighlightsGlobeNewswire
ASMB
Earnings
- 5/8/24 - Beat
ASMB
Analyst Actions
- 4/1/24 - HC Wainwright
ASMB
Sec Filings
- 5/8/24 - Form 10-Q
- 5/8/24 - Form 8-K
- 5/1/24 - Form 4
- ASMB's page on the SEC website